Isolated hepatic perfusion (IHP) has been tried by several researchers, and promising results have been obtained (1-6). The rationale for this is based on minimizing the systemic side effects of cytotoxic drugs by excluding the perfused liver from the systemic circulation. Although this modality has yielded encouraging results, it has not been used as a therapeutic strategy because it requires aggressive surgical intervention and can be performed only once.Percutaneous IHP techniques using balloon occlusion catheters are simpler and facilitate repeated therapy, but result in far...

Animals: Eight male pigs weighing 39 to 43 kg (mean: 42 kg) were used.Procedures: We performed a retrograde outflow IHP with a double balloon blocking outflow into IVC and allowing outflow via the portal vein. Blood with cisplatin (2.5 mg/kg) in the extracorporeal circuit was circulated in the liver with rotary pumps under isolation with balloon catheters (Figure 1).Examination items: 1) Hepatic angiographic examinations during perfusion 2) Histopathologic examinations after perfusion 3) Pharmacokinetics; the maximum platinum concentration (C-max), concentration-time curve (AUC)

I. Hepatic angiographic examinations during perfusion II. Histopathologic examinations for organs after perfusion III. Pharmacokinetics; The maximum platinum concentration (C-max) The concentration-time curve (AUC)

Repeatable percutaneous retrograde IHP therapy with only interventional radiology techniques may be realize, safety and useful for management of liver tumors.

1. de Vries MR, Rinkes IH, van de Velde CJ, et al. (1998) Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147:107–19.2. Alexander Jr HR, Bartlett DL, Libutti SK (2000) Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist 5(5):416–424.3. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. (2000) Increased local cytostatic drug exposure by...

Satoru Murata MD, PhD.Department of Radiology,Head of Interventional Radiology Center,Nippon Medical School,1-1-5 Sendagi, Bunkyo-ku, Tokyo, JapanTel: 81-35814-6240Fax: 81-35685-1795E-mail: [email protected]